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Abstract: Background: Here we examined myocardial microRNA (miRNA) expression profile in
a sensory neuropathy model with cardiac diastolic dysfunction and aimed to identify key mRNA
molecular targets of the differentially expressed miRNAs that may contribute to cardiac dysfunction.
Methods: Male Wistar rats were treated with vehicle or capsaicin for 3 days to induce systemic sensory
neuropathy. Seven days later, diastolic dysfunction was detected by echocardiography, and miRNAs
were isolated from the whole ventricles. Results: Out of 711 known miRNAs measured by miRNA
microarray, the expression of 257 miRNAs was detected in the heart. As compared to vehicle-treated
hearts, miR-344b, miR-466b, miR-98, let-7a, miR-1, miR-206, and miR-34b were downregulated, while
miR-181a was upregulated as validated also by quantitative real time polymerase chain reaction
(qRT-PCR). By an in silico network analysis, we identified common mRNA targets (insulin-like
growth factor 1 (IGF-1), solute carrier family 2 facilitated glucose transporter member 12 (SLC2a-12),
eukaryotic translation initiation factor 4e (EIF-4e), and Unc-51 like autophagy activating kinase 2
(ULK-2)) targeted by at least three altered miRNAs. Predicted upregulation of these mRNA targets
were validated by qRT-PCR. Conclusion: This is the first demonstration that sensory neuropathy
affects cardiac miRNA expression network targeting IGF-1, SLC2a-12, EIF-4e, and ULK-2, which may
contribute to cardiac diastolic dysfunction. These results further support the need for unbiased
omics approach followed by in silico prediction and validation of molecular targets to reveal
novel pathomechanisms.
Int. J. Mol. Sci. 2019, 20, 991; doi:10.3390/ijms20040991 www.mdpi.com/journal/ijms
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1. Introduction
Polyneuropathy including sensory neuropathy is one of the most common long-term complication
of diabetes mellitus [1], which occurs in more than 50% of patients with long-standing diabetes [2];
for a review, see [3]. Diabetes is a well-established comorbidity of cardiovascular diseases including
acute myocardial infarction (AMI) and heart failure (HF). Diabetic sensory neuropathy [4], see [3] for a
review, affects the heart due to its rich sensory innervations [1,5].
Systemic administration of appropriate dose of capsaicin, a highly selective sensory neurotoxin,
leads to a selective dysfunction of a morphologically well-defined group of primary sensory
nerves [6–8]. Therefore, sensory desensitization induced by systemic capsaicin treatment is a
well-accepted model to investigate the pathology and pharmacology of sensory neuropathy, see [9,10]
for reviews. Cardiac sensory nerves play a pivotal role in myocardial adaptation processes to ischemic
injury including ischemic pre-, post-, and remote conditioning [11–13]. We have previously shown
that capsaicin-induced sensory neuropathy has led to cardiac diastolic dysfunction characterized by
increased left ventricular end-diastolic pressure via different pathways dependent on nitric oxide
and sarcoplasmic reticulum calcium ATPase [11,14,15]. Furthermore, capsaicin-induced sensory
neuropathy has affected the expression profile of cardiac mRNAs [16]. Therefore, it was feasible to
speculate that systemic sensory desensitization may also affect microRNA expression in the heart.
MicroRNAs (miRNAs) are 17–25 nucleotide-long noncoding RNAs inhibiting gene expression
at posttranscriptional level via blocking of translation or enhanced degradation of messenger RNAs
(mRNA) in a tissue specific manner, see [17–19] for reviews. To date, the number of identified miRNAs
exceeds 35,000 in over 200 different species (http://www.mirbase.org). miRNAs are able to target
several mRNAs and most mRNAs have different binding sites for multiple miRNAs; see [17] for a
review. Many miRNAs have been identified in cardiovascular physiology or pathologies such as
coronary artery stenosis, acute coronary syndrome, acute myocardial infarction, unstable angina,
hypertension, heart failure, cardiomyopathies, etc., see [17–19] for reviews. Moreover, several altered
miRNAs have been identified in the heart of diabetic animals or patients (see [20] for a review)
and in diabetic complications (see [21] for a review) including diabetic neuropathy and sensory
desensitization; see [3] for a review.
To identify molecular targets involved in disease pathomechanisms, the use of unbiased omics
approach followed by in silico analysis of molecular networks are emerging, see [22] for a recent
position paper. MiRNA omics followed by in silico target prediction and experimental validation
of molecular targets are useful unbiased workflow for the identification of novel pathomechanisms
and potential molecular targets [22–24]. Therefore, the aim of the present study was to identify
novel mechanisms involved in cardiac diastolic dysfunction induced by sensory neuropathy by an
unbiased workflow according to the recent recommendations of the European Society of Cardiology,
Working Group of Cellular Biology of the Heart [22]. Accordingly, here we measured the cardiac
miRNA expression profile followed by in silico miRNA–mRNA target interaction network analysis
and experimental validation of predicted mRNA targets in a rat model of capsaicin-induced
sensory neuropathy.
2. Results
2.1. Basic Characteristics
Body and heart weights were measured at baseline and at the 10th day, 7 days after the last
capsaicin dose. Body weight and heart weight were significantly lower at the 10th day in sensory
neuropathic group as compared to the vehicle-treated control group (Table 1). The sensory neuropathic
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animals gained significantly less weight as compared to the control animals (Table 1). The development
of sensory neuropathy was confirmed in all animals treated with capsaicin by eye-wipe behavioral test.
No mortality occurred either during capsaicin or vehicle treatment or during the 7-day follow-up.
Table 1. Effect of sensory neuropathy on body and heart weights.
BW 0 BW 10 ∆BW (10–0) HW HW/BW
(g) (g) (g) (mg) (‰)
Control 339 ± 25 380 ± 40 41 ± 20 1167 ± 116 3.1 ± 0.2
Sensory Neuropathy 328 ± 16 335 ± 17 * 7 ± 5 ** 972 ± 98 * 2.9 ± 0.2
BW 0, body weight at baseline; BW 10, body weight at 7th day after last capsaicin injection; and HW, heart weight.
Values are shown as means ± SD (n = 6 in each group; * p < 0.05 versus control, ** p < 0.01 versus control; unpaired
Student’s t-test).
2.2. Myocardial Function
Capsaicin-induced sensory neuropathy significantly altered functional parameters in the heart
compared to vehicle-treated group as assessed by transthoracic echocardiography. Among other
parameters (see Table 2) in sensory neuropathic hearts, end-diastolic diameter (EDD; for representative
M-mode images, see Supplementary Figure S1), interventricular septum thickness (IVS), stroke
volume (SV), as well as mitral valve velocity time index (MVVTI) were significantly decreased as
compared to the vehicle-treated control group. Furthermore, Aa/Ea ratio showed as light decreasing
tendency in sensory neuropathy group. Systolic performance of the heart did not show any difference
between the two groups.
Table 2. Effect of sensory neuropathy on myocardial morphology and function assessed by
transthoracic echocardiography.
Parameter Control Sensory Neuropathy p-Value
Heart rate 412 ± 32 441 ± 35 0.30
EDD (cm) 0.69 ± 0.05 0.62 ± 0.03 0.03 *
ESD (cm) 0.40 ± 0.10 0.36 ± 0.05 0.46
IVS (cm) 0.15 ± 0.01 0.13 ± 0.01 0.04 *
PW (cm) 0.16 ± 0.01 0.15 ± 0.01 0.12
EDV (ml) 0.70 ± 0.18 0.54 ± 0.07 0.14
ESV (ml) 0.18 ± 0.10 0.12 ± 0.05 0.30
SV (EDV–ESV) 0.54 ± 0.07 0.42 ± 0.07 0.03 *
LVEF (%) 75.83 ± 9.89 77.57 ± 8.46 0.79
LVFS (%) 41.14 ± 9.77 41.89 ± 7.35 0.90
MVVTI (cm) 4.14 ± 0.36 3.23 ± 0.75 0.04 *
E (cm/sec) 80.67 ± 14.40 65.2 ± 11.39 0.11
A (cm/sec) 59.50 ± 27.87 53.2 ± 31.22 0.76
Ea (cm/sec) 6.33 ± 1.25 6.20 ± 3.19 0.93
Aa (cm/sec) 5.50 ± 1.71 6.40 ± 1.36 0.41
Sa (cm/sec) 5.00 ± 1.15 5.60 ± 1.85 0.57
E/Ea 13.07 ± 3.02 13.03 ± 5.44 0.99
Ea/Aa 1.26 ± 0.44 0.98 ± 0.48 0.23
Data are shown as mean ± SD., n = 5–6; * p < 0.05; unpaired Student’s t-test. EDD, end-diastolic diameter; ESD,
end-systolic diameter; IVS, interventricular septum; PW, posterior wall thickness; EDV, end-diastolic volume; ESV,
end-systolic volume; SV, stroke volume; EF, ejection fraction; FS, fractional shortening; MVVTI, mitral valve velocity
time index; E, wave for early diastolic filling; A, wave for atrial filling.
2.3. miRNA Microarray Analysis
To detect the alteration in miRNA expression profile of sensory neuropathic hearts, we performed
miRNA microarray. Out of the 711 known miRNAs, the expression of 257 miRNAs was detectable.
Out of the detected 257 miRNAs, miR-344b and miR-466b showed significant downregulation and
miR-181a was upregulated as compared to the vehicle-treated control (Table 3). Despite miR-98, let-7a,
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miR-1, and miR-206 as well as miR-34b not showing significant changes in sensory neuropathic animals
as compared to controls, we selected these miRNAs for further analyses since their log2 ratios were
<−0.6 and >0.6, respectively (Table 3).
Table 3. Expression of selected microRNAs (miRNAs) by microarray analysis.
miRNA Average log2 ChangeSensory Neuropathy/Control Log2 SD Regulation
rno-miR-344b-1-3p −1.95 * 0.47 down
rno-miR-466b-1-3p −1.10 * 0.49 down
rno-miR-98-5p −1.07 1.26 down
rno-let-7a-5p −1.03 1.21 down
rno-miR-1-3p −0.88 1.19 down
rno-miR-206-3p −0.86 1.23 down
rno-miR-34b-3p 0.63 0.46 up
rno-miR-181a-2-3p 0.75 * 0.27 up
Gene expression ratio with p-value < 0.05 and log2 ratio < −0.6 or log2 ratio > 0.6 (~1.5 fold change) are considered
as repression and overexpression, respectively. SD, standard deviation; * p < 0.05 versus control; unpaired unequal
variance Student’s t-test.
2.4. Validation of miRNA Microarray Results by qRT-PCR
In order to validate miRNA microarray analysis, we used qRT-PCR (Table 4). Significant
downregulation of miR-466b, miR-98, let-7a, miR-1, and miR-206 as well as upregulation of miR-181a
were confirmed by qRT-PCR (Table 4). miR-34b showed a significant downregulation by qRT-PCR
(Table 4); however, it showed a non-significant upregulation in the microarray (Table 3). The expression
of miR-344b could not be detected by qRT-PCR (Table 4). The expression changes of 6 out of 8 selected
microRNAs were confirmed by qRT-PCR, which shows an acceptable rate of confirmation of the
microarray data [25–28].
Table 4. Validation of microarray analysis by qRT-PCR.
miRNA Average log2 Change SensoryNeuropathy/Control log2 SD Fold Change Regulation Confirmation
rno-miR-344b-1-3p n.d. n.d. n.d. n.d. n.d.
rno-miR-466b-1-3p −3.19 * 1.59 −9.13 * down yes
rno-miR-98-5p −2.45 ** 1.19 −5.48 ** down yes
rno-let-7a-5p −2.03 ** 0.54 −4.07 ** down yes
rno-miR-1-3p −2.85 ** 1.03 −7.21 ** down yes
rno-miR-206-3p −5.19 ** 1.58 −36.42 ** down yes
rno-miR-34b-3p −2.93 ** 1.76 −7.60 ** down no
rno-miR-181a-2-3p 3.81 ** 1.55 14.03 ** up yes
SD, standard deviation; n.d., non-detectable; * p < 0.05, ** p < 0.01 versus control; two tailed two sample unequal
variance Student’s t-test.
2.5. In Silico Network Analysis
In order to determine targets of the altered miRNAs, we used a previously validated software [23]
relying on 3 publicly available online databases and illustrated the results on a miRNA–target network.
We identified 15 target genes with high miRNA connectivity (≥degree 3) (Figure 1, dark blue spots).
Out of 15 genes, we selected 4 targets based on available literature related to myocardial function
and/or diabetes. Insulin-like growth factor-1 (IGF-1) was regulated by miR-466b, miR-1, and miR-206;
solute carrier family 2 facilitated glucose transporter member 12 (SLC2a-12) was regulated by miR-466b,
miR-98, and let-7a; eukaryotic translation initiation factor 4e (EIF-4e) was regulated by miR-1, miR-206,
and miR-34b; and Unc-51 like autophagy activating kinase 2 (ULK-2) was regulated by miR-98, let-7a,
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and miR-34b (Figure 1, Table 5). Each of these miRNAs were downregulated by capsaicin treatment in
the heart. For more miRNA–target connections, see Table S1.
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All miRNAs for the selected gene targets showed downregulation in the sensory neuropathy group 
as compared to the control. Plus signs (+) show the related miRNAs for each target mRNA molecules. 
2.6. Validation of Gene Targets at mRNA Level 
We  investigated  the mRNA  level of  the  4  selected gene  targets by qRT‐PCR  to validate  the 
results of microarray and in silico network analysis (a representative agarose gel image of amplified 
Figure 1. Representative image for in silico network analysis of the possible gene targets of the 8 altered
miRNAs based on online databanks. Red nodes present miRNAs, blue nodes mark the predicted
targets. Dark blue nodes label the target genes with≥3 miRNA connections. Edges (gray lines) between
nodes represent predicted miRNA–target interactions. (a) and (b) panels are presented in a magnified
manner to help better perceive them.
Table 5. Selected target genes indicating their miRNA connections by plus sign (+).
Target Regulated by
Abbreviation Name miR-466b miR-98 let-7a miR-1 miR-206 miR-34b
IGF-1 Insulin-like growth factor-1 + + +
SLC2a-12 Solute carrie family 2 facilitatedglucose transporter member 12 + + +
EIF-4e Eukaryotic translation initiationfactor 4e + + +
ULK-2 Unc-51 like autophagy activatingkinase 2 + + +
All miRNAs for the selected gene targets showed downregulation in the sensory neuropathy group as compared to
the control. Plus signs (+) show the related miRNAs for each target mRNA molecules.
2.6. Validation of Gene Targets at mRNA Level
We investigated the mRNA level of the 4 selected gene targets by qRT-PCR to validate the results
of microarray and in silico network analysis (a representative agarose gel image of amplified cDNA
transcript is available in Supplementary Figure S2). The levels of mRNAs were significantly elevated
in the case of IGF-1, SLC2a-12, EIF-4e, and ULK-2 in th sens ry neuropathic group as compared to the
controls (Figure 2 A–D). We used GAPDH for internal control, because GAPDH levels were similar in
both control and sensory neuropathic heart samples (Figure S3).
Int. J. Mol. Sci. 2019, 20, 991 6 of 19
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW  6  of  19 
 
cDNA transcript is available in Supplementary Figure S2). The levels of mRNAs were significantly 
elevated  in  the  case  of  IGF‐1,  SLC2a‐12, EIF‐4e,  and ULK‐2  in  the  sensory  neuropathic  group  as 
compared  to  the controls  (Figure 2 A–D). We used GAPDH  for  internal control, because GAPDH 
levels were similar in both control and sensory neuropathic heart samples (Figure S3). 
 
Figure 2. mRNA levels of (A) IGF‐1 (insulin‐like growth factor 1), (B) SLC2a‐12 (solute carrier family 
2 facilitated glucose transporter member 12), (C) EIF‐4e (eukaryotic translation initiation factor 4e), 
and (D) ULK‐2 (Unc‐51 like autophagy activating kinase 2) in sensory neuropathic rat heart samples 
as compared to vehicle‐treated controls (control). The transcript levels were normalized to GAPDH 
(glyceraldehyde‐3‐phosphate dehydrogenase). Data are expressed in arbitrary units as means ± SD. 
(n = 5–6, * p < 0.05, ** p < 0.01 versus control; unpaired Student’s t‐test). 
3. Discussion 
Here, we have shown that sensory neuropathy induced by systemic capsaicin treatment leads 
to the downregulation of 7 miRNAs and to the upregulation of 1 miRNA in the rat heart. Based on 
the alteration of these miRNAs, in silico miRNA–mRNA target network analysis predicted changes 
in  the  expression  of  IGF‐1,  SLC2a‐12,  EIF‐4e,  and  ULK‐2  genes,  which  was  then  validated  by 
qRT‐PCR in the heart. This is the first demonstration that sensory neuropathy affects cardiac miRNA 
expression network targeting IGF‐1, SLC2a‐12, EIF‐4e, and ULK‐2, which may contribute to cardiac 
diastolic dysfunction  induced by  sensory neuropathy. These  results  further  support  the need  for 
unbiased omics approach followed by in silico prediction and validation molecular targets to reveal 
novel  pathomechanisms  according  to  the  recent  recommendations  of  the  European  Society  of 
Cardiology Working Group of Cellular Biology of the Heart [22]. 
3.1. Altered Cardiac Function Due to Sensory Neuropathy 
Here,  we  found  that  in  vivo  cardiac  diastolic  function  was  impaired  by  capsaicin 
desensitization, which supports our previous ex vivo functional data [11,14]. End‐diastolic diameter 
and interventricular septum thickness as well as stroke volume and mitral valve velocity time index 
were significantly decreased as compared to the vehicle‐treated control group. Furthermore, Aa/Ea 
ratio showed a slight decreasing  tendency  in sensory neuropathy group, which  indicated cardiac 
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Figure 2. mRNA levels of (A) IGF-1 (insulin-like growth factor 1), (B) SLC2a-12 (solute carrier family
2 facilitated glucos transporter member 12), (C) EIF-4e (euka yotic translation initiation factor 4e),
and (D) ULK-2 (Unc-51 like au ophagy activating kinase 2) in sensory neuropathic rat heart samples
as compared to vehi le-treated c ntrols (control). The transcript levels were normalized to GAPDH
(gly eraldehyde-3-p osphate dehydrogenase). Data are expressed in arbitrary units as means ± S .
(n = 5–6, * p < 0.05, ** p < 0.01 versus control; unpaired Student’s t-test).
3. Discussion
Here, we have shown that sensory neuropathy induced by systemic capsaicin treatment leads to
the downregulation of 7 miRNAs and to the upregulation of 1 miRNA in the rat heart. Based on the
alteration of these miRNAs, in silico miRNA–mRNA target network analysis predicted changes in
the expression of IGF-1, SLC2a-12, EIF-4e, and ULK-2 genes, which was then validated by qRT-PCR in
the heart. This is the first demonstration that sensory neuropathy affects cardiac miRNA expression
network targeting IGF-1, SLC2a-12, EIF-4e, and ULK-2, which may contribute to cardiac diastolic
dysfunction induced by sensory neuropathy. These results further support the need for unbiased
omics approach followed by in silico prediction and validation molecular targets to reveal novel
pathomechanisms according to the recent recommendations of the European Society of Cardiology
Working Group of Cellular Biology of the Heart [22].
3.1. Altered Cardiac Function Due to Sensory Neuropathy
Here, we found that in vivo cardiac diastolic function was impaired by capsaicin desensitization,
which supports our previous ex vivo functional data [11,14]. End-diastolic diameter and
interventricular septum thickness as well as stroke volume and mitral valve velocity time index
were significantly decreased as compared to the vehicle-treated control group. Furthermore, Aa/Ea
ratio showed a slight decreasing tendency in sensory neuropathy group, which indicated cardiac
diastolic dysfunction according to previously published data [29].
The physiological and pathophysiological roles of sensory nerves in cardiac function in the healthy
or diseased heart is somewhat neglected in the literature, therefore, little is known about it. However,
some mechanisms have been described, including, e.g., regulation of cardiac contractility by different
neuropeptide and nitric oxide-mediated mechanisms [14,16,30–35]. Therefore, here we used an
unbiased non-hypothesis driven miRNA transcriptomics-based workflow to identify novel molecular
targets that may be involved in the mechanisms of cardiac dysfunction caused by sensory neuropathy.
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3.2. Altered Cardiac miRNAs Expression Profile due to Sensory Neuropathy
By using the unbiased omics approach to reveal global cardiac miRNA expression changes,
we have shown the downregulation of miR-344b, miR-466b, miR-98, let-7a, miR-1, miR-206, miR-34b,
and an upregulation of miR-181a in the heart in a rat model of sensory neuropathy induced by systemic
capsaicin treatment. Regarding miR-1 and miR-206 downregulation in the heart, concordant results
were shown in the soleus muscle after sciatic nerve denervation [36,37]. miR-1 and miR-206 belong
to “myomir” network having a potent role in cardiac and skeletal muscle development, regulation,
and remodeling, see [17,38,39] for reviews. Previously, we have found an increase in superoxide
dismutase-1 (SOD1) and a decrease in endothelial nitrogen monoxide synthase (eNOS) activities as well
as a reduction of nitrogen monoxide (NO) levels in hearts of sensory desensitized rats [11,14,15]. In line
with this, SOD1 expression was repressed in dog hearts overexpressing miR-206 [40], and the protein
level of SOD1 was decreased under oxidative conditions in miR-1 overexpressing mice [41]. Moreover,
in this sensory neuropathy model, we have previously shown that cardiac level of S-nitrosylated
SERCA2a was decreased [14]. Other studies showed connection between SERCA2a and miR-1 in the
heart [42,43]: miR-1 was downregulated in post-infarction heart failure in rats, and its expression was
normalized via reversed remodeling by adenoviral SERCA2a gene delivery [42]. In different diabetic
conditions, the alteration of miR-1 and miR-206 seems to be less clear. Cardiac miR-1 and miR-206 were
downregulated 2 months (mice) or 5 weeks (rats) after induction of diabetes by streptozotocin (STZ)
treatment [44,45], and miR-206 was downregulated in vascular smooth muscle cells in hyperglycemic
conditions [46]. In contrast, others found that both miRNAs were upregulated in hearts of STZ-treated
rats 2 weeks after STZ injection [47]. However, in these diabetic models sensory neuropathy was not
investigated. Further studies proved that downregulation of miR-1 contributes to pathological cardiac
hypertrophy including diabetic cardiomyopathy, see [38,39] for reviews, but others found upregulation
in human cardiomyopathies or heart failure [48]. Moreover, miR-1 expression was also increased in
AMI patients [49,50], as well as in rodents during ischemic pre- or postconditioning [26,51].
MiR-98 and let-7a were downregulated in the present capsaicin-induced sensory neuropathy
model. Both miRNAs belong to the let-7 family, see [52] for a review. Bao et al. have found that let-7a
overexpression resulted in an increase in eNOS expression and NO content in endothelial cells [53],
which conforms to our previous and present findings in sensory neuropathic animals, i.e., let-7a was
downregulated as well as eNOS expression and NO content were decreased in the heart [14]. Moreover,
previous studies showed that let-7a were downregulated in the hearts of diabetic mice [54] as well as
in the serum of diabetic patients [55] or in heart samples of rodent AMI models [26,56,57]. Only a few
publications are available for investigating miR-98 in connection with sensory neuropathy or cardiac
pathologies. Downregulation of miR-98 was shown to lead to the upregulation of cyclin D2, which is
involved in the vascular complications of type 2 diabetes mellitus [58,59], and upregulation of miR-98
prevented cardiac hypertrophy via inhibition of cyclin D2 [60]. Here, we also identified cyclin D2
(Ccnd2) as a possible target for miR-98 (Figure 1).
We found here that miR-34b was repressed in sensory neuropathy. There is no available literature
about the alteration of miR-34b in neuropathic models. Previous studies described upregulation of
miR-34b in hearts of patients with diabetes or with end-stage heart failure [61,62]. Inhibition of miR-34
family (miR-34a, -34b, and -34c) by an anti-miR improved cardiac function and prevented remodeling
in mice after AMI or in pressure overload-induced cardiac hypertrophy [63]. Therefore, mir-34b and its
targets may be involved in the diastolic dysfunction of the heart observed in the present study.
Although we found repression of miR-466b and miR-344b in sensory neuropathy model, there is a
gap in the literature investigating the role of these miRNAs in the heart or in diabetes or in neuropathy
models. A previous study showed that miR-466b is downregulated in neuronal stem cells isolated
from embryos of hyperglycemic pregnant mice [64]. Liu et al. have previously identified miR-344b in
the developing mouse brain, but they have not found miR-344b in the embryonic mouse heart [65].
Based on the above-mentioned previous findings, we can hypothesize that miR-466b and miR-344b
may rather be derived from cardiac neural cells than from cardiomyocytes.
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miR-181a was the only miRNA, which showed significant upregulation in our present study.
miR-181a was downregulated in exercise-induced cardiac hypertrophy in rats [66]. However, miR-181
was upregulated in the serum of diabetic patients [67,68] and during acute ischemia/reperfusion
injury or in ischemic preconditioning in rats [26]. We have previously found that myocardial ROS
production including NO and peroxynitrite levels were decreased in capsaicin-induced neuropathy
model [14], which may be related to the roles of NO and peroxynitrite in myocardial ischemia or
in cardiac preconditioning. Thus, it seems that miR-181a contributes to cardiac pathologies—it is
upregulated during acute injuries and repressed in chronic disease states.
3.3. In Silico miRNA–mRNA Target Prediction
In the present study, we successfully applied and further validated the recently developed
miRNAtarget™ software [23] to identify the possible targets of the altered miRNAs according to our
results of experimental validation of predicted targets (see Section 4.4.). Several different sources of
possible miRNA–target gene interactions (MTIs) on various level of maturity are available publicly;
however, none of them provide a comprehensive solution for finding all existing MTIs for any
randomly selected miRNA. While experimentally validated and manually curated MTI databases
such as TarBase [69] or MirTarBase [70] contain only a limited set of possible interactions, available
MTI prediction algorithms, e.g., miRanda for microrna.org [71,72], TargetScan [73], PITA [74] in
the most cases consider only one or few important aspects of the complex biological setting of
post-transcriptional regulation by miRNAs, like seed region complementarity [71,73], 3D structure and
accessibility of binding site [74], thermodynamical stability of the miRNA–mRNA complex [71],
evolutionary conservation of miRNA sequences [71], mutual evolution of miRNA seed regions
and binding sites on targets [74], possible miRNA synergisms [75], or modulation of the MTIs by
RNA-binding proteins [76]. These limitations imply a high degree of uncertainty when relying on
predicted MTI data even in the case of MTI databases populated by machine learning algorithms
like MirTarget for miRDB [77]. Thus to reduce the probability of false positive results or omitting
crucial interactions, the miRNAtarget™ relies on multiple MTI databases and implements a simple yet
powerful network theoretical approach as described previously [23].
3.4. Altered Cardiac Target mRNAs due to Sensory Neuropathy
We identified 15 target genes with high miRNA connectivity (≥degree 3) (Figure 1, dark blue
spots). Out of these 15 predicted genes, we selected 4 target genes (IGF-1, SLC2a-12, EIF-4e, and ULK-2)
based on the available literature related to myocardial function and/or diabetes for experimental
validation. As target validation by qRT-PCR is considered to be a strong experimental evidence for
miRNA–target interaction even by the most popular manually curated miRNA–target interaction
database [78], we measured target expressions on the mRNA level by qRT-PCR. In case of all the 4
selected miRNA targets, we found significant upregulation at the mRNA level by qRT-PCR, which is
in line with the expected expression changes, as all 4 targets were predicted to interact with at least
two downregulated miRNAs. However, transfection-based experimental validation of the targets was
out of the scope of our study.
Overexpression of IGF-1 was found in the sensory neuropathic animals as a possible consequence
of downregulation of miR-1, miR-206, and miR-466b. It has been described that IGF-1 affects the
receptors of capsaicin (Transient Receptor Potential Vanilloid 1, TRPV1; [79,80]) and vice versa,
capsaicin via TRPV1 receptors increases cardiac IGF-1 level [81]. Furthermore, IGF-1 levels have
been shown to be reduced in diabetic peripheral neuropathy in the heart [82], extensively reviewed
in [83]; however, we found here an upregulation of IGF-1 gene in sensory neuropathy in the absence
of hyperglycemia. Moreover, cardiac expression of IGF-1 is altered in a variety of cardiovascular
diseases [84,85], see [86] for a review. All of these pathologies are characterized by an initial
upregulation of IGF-1 and IGF-1R, which have been suggested to be involved in cardiac remodeling
response [84,86]. Finally, a powerful regulatory link was recently shown in the heart between IGF-1 and
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miR-1 in a mouse model of pressure-overload-induced heart failure [87]. This IGF-1–miR-1 connection
was confirmed by our data in sensory neuropathy.
We found that SLC2a-12 (or GLUT-12) was regulated by miR-98, let-7a, and miR-466b, and its
myocardial mRNA level increased after systemic-capsaicin-treatment-induced sensory neuropathy.
SLC2a-12 is an insulin sensitive glucose transporter [88,89]. Increased active SLC2a-12 content was
observed at the surface of diabetic cardiomyocytes as a compensation of GLUT-4 downregulation
during diabetes [90]. Our results suggest that sensory neuropathy, as a complication of diabetes may
lead to the downregulation of let-7a (see above) and thereby to overexpression of SLC2a-12 in the heart.
In the present study, mRNA level of EIF-4e increased likely through the downregulation of miR-1,
miR-206, and miR-34b. EIF-4e may affect protein synthesis as a downstream target of IGF-1–mTOR
(mammalian target of rapamycin) pathway [91,92]. Dysregulation of this pathway may contribute to
the development of both heart failure or type 2 diabetes, see [91] for a review.
In the present study, the expression of ULK-2, an autophagy activating protein, was increased as
a possible consequence of downregulation of miR-98, let-7a, and miR-34b. It has already been shown in
many cell types that capsaicin is able to induce autophagy [93,94]; however, the effect of high-dose
capsaicin treatment on cardiac autophagy has not been investigated yet. Moreover, involvement of
autophagy in cardiac complications of diabetes has also been described; however, its exact role is still
not clear, see [95] for a review. In summary, our results suggest that autophagy may be altered in
sensory neuropathy; however, further experiments are needed to clarify its exact mechanism.
3.5. Study Limitations
In the present study, the confounding effects of cardiovascular comorbidities and risk factors
(e.g., age and sex) have not been studied, which is an obvious limitation of the study [96]; however,
such experiments would have exceeded the scope of the present MS.
It is known that primary sensory afferents may influence blood glucose level due to several
mechanisms, including morphological and functional interactions between the capsaicin receptor
TRPV1 and the insulin receptor in the pancreas [97]. Moreover, we have found in the present study
that IGF-1 was overexpressed in sensory neuropathic animals; however, this finding was a result of
an unbiased non-hypothesis driven workflow. Therefore, in the experimental protocol, we have not
included glucose measurements; however, after revealing the results of the current unbiased study
workflow, it is now evident that glucose measurements would have been an interesting addition to the
present study.
In this study, we used only one method, i.e., qRT-PCR for the validation of the microRNA–mRNA
target predictions, which is considered as a strong experimental evidence for microRNA–target
interaction even according to the most popular manually curated microRNA–target interaction
database [78]. Although several other methods including luciferase assays, target binding using
variant seed sequence constructs, etc. are available, multiple target validation would have exceeded
the scope of this study. Moreover, although, it is well-known that beyond mRNA degradation, miRNAs
could also regulate protein expression via inhibition of translation by coupling to specific mRNA
sequences [98], we have not investigated the effects of the altered miRNAs on translation or on
protein level; therefore, our present study is restricted to translational downregulation of genes by
miRNA targeting.
4. Materials and Methods
The present study conforms to the EU directive about the care and use of laboratory animals,
published by the European Union (2010/63/EU) and was approved by the Ethics Committee for
Animal Research of the University of Szeged. The animals were housed in individually ventilated
cages (Sealsafe IVC system, Tecniplast S.p.a., Varese, Italy) which conform the size recommendations
of the abovementioned EU guidelines. Litter material (Lignocell hygienic animal bedding) placed
beneath the cage has been changed at least three times/week. The animal room was temperature
Int. J. Mol. Sci. 2019, 20, 991 10 of 19
controlled (22 ± 2 ◦C), had a 12-h light/dark cycle with lights on at 7 am to 7 pm. The animals were
acclimatized in the housing facilities for 5 days prior to the start of the animal experiments. Animals
were fed a standard rodent chow and filtered tap water ad libitum.
4.1. Induction of Selective Sensory Neuropathy by Systemic Capsaicin Treatment
It is well-established that selective sensory neuropathy can be induced by systemic
capsaicin-induced desensitization. Systemic capsaicin treatment at appropriate doses induces
a selective impairment of C-fiber primary sensory neurons expressing the capsaicin receptor
TRPV1 [99–101]; which can be observed by, e.g., depletion of cardiac CGRP-containing afferent
nerves [11]. Systemic capsaicin-desensitized animals have elevated chemical and heat pain thresholds,
show no signs of pain, irritation or discomfort, and behave similar to controls [102].
Twelve male Wistar rats weighing 300–350 g were used throughout the experiments. General
anesthesia was induced by the inhalation of 5% isoflurane and maintained with 2% for 10 min.
Two minutes before the induction of volatile anesthesia, animals received 0.3 mg/kg nalbuphin
to alleviate pain due to capsaicin treatment. Capsaicin (1% w/v, Fluka, Buchs, Switzerland) was
administered subcutaneously (n = 6) on consecutive days at increasing doses of 10, 30, and 50 mg/kg,
respectively, as described previously [11]. Ten minutes after capsaicin injection, isoflurane anesthesia
was finished. Animals (n = 6) treated with the solvent for capsaicin (6% v/v ethanol and 8% v/v
Tween 80 in physiological saline) served as controls. Seven days after the last injection of capsaicin,
when depletion of TRPV1-expressing CGRP-containing myocardial sensory nerves is apparently
complete [11], the body weights of the animals were measured. To confirm the development of sensory
neuropathy in capsaicin-treated rats, eye-wipe behavioral test was performed before and after systemic
capsaicin treatment [11,103,104]. Before capsaicin treatment, all the animals showed intensive eye wipe
behavior after dropping 50 µL, 0.1% capsaicin into the left eye; however, 7 days after systemic capsaicin
treatment, eye wipe behavior showed more than 10-fold decrease in capsaicin-treated animals.
Seven days after capsaicin treatment, hearts were excised under deep Na-pentobarbital
(60 mg/kg ip.) anesthesia. To wash out blood, the hearts were perfused according to Langendorff for
5 min at 37 ◦C with Krebs–Henseleit bicarbonate buffer [105]. After perfusion, hearts were weighed
and frozen immediately in liquid nitrogen, pulverized, and stored at −80 ◦C.
4.2. Transthoracic Echocardiography
The transthoracic echocardiography was performed in a blinded manner using a commercially
available ultrasound machine (Vivid 7 Dimension, GE Medical Systems, Horten, Norway) equipped
with a 2.5–3.5 MHz phased array sector scan probe, second harmonic technology, and coupled with
tissue Doppler imaging (TDI). The left ventricular diameter, wall thickness, volume, and ejection
fraction were measured from parasternal long-axis view using M-mode images. The left ventricular
stroke volume was assessed from the diameter of the left ventricular outflow tract (LVOT), and time
velocity integral of the LVOT was measured by pulsatile Doppler. LV diastolic function was determined
from the velocities of mitral inflow by pulsed Doppler echocardiography complemented with mitral
annular velocity of TDI.
4.3. Isolation of miRNAs
To 50 mg tissue powder, 190 µL proteinase K solution was added including 120 µL paraffin tissue
lysis buffer (Roche, Mannheim, Germany). Samples were incubated at 55 ◦C for 30 min, and a two-step
purification protocol was performed as described previously [106]. The quality and quantity of the
isolated miRNA and total RNA were assessed spectrophotometrically (NanoDrop1000 Version 3.8.1.
Thermo Fisher Scientific, Waltham, MA, USA) and with 2100 Bioanalyzer (Agilent Technologies Inc.,
Santa Clara, CA, USA). Three heart samples of the RNA extracted from the 6 different samples in each
group were pooled, and the obtained 2 samples/group were assayed on the microarrays.
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4.4. miRNA Microarray
Microarray analysis was conducted at Exiqon Services, Vedbaek, Denmark. The quality of the
total RNA was verified by an Agilent 2100 Bioanalyzer profile (Agilent Technologies Inc., Santa Clara,
CA, USA). Three-hundred and fifty nanograms of miRNA from both sample and control was
labeled with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY LNA™ microRNA
Hi-Power Labeling Kit, Hy3™/Hy5™ (Exiqon, Vedbaek, Denmark) following the procedure described
by the manufacturer. Briefly, Hy3™-labeled samples and a Hy5™-labeled control RNA sample
were mixed pair-wise and hybridized to the miRCURY LNA™ microRNA Array 7th Gen (Exiqon,
Vedbaek, Denmark), which contains capture probes targeting all microRNAs for human, mouse or rat,
registered in the miRBASE 18.0. The hybridization was performed according to the miRCURY LNA™
microRNA Array Instruction manual using a Tecan HS4800™ hybridization station (Tecan Austria
GmbH, Grödig, Austria). After hybridization, the microarray slides were scanned and stored in an
ozone-free environment (Ozone level below 2.0 ppb) in order to prevent potential bleaching of the
fluorescent dyes. The miRCURY LNA™ microRNA Array slides were scanned using the Agilent
G2565BA Microarray Scanner System (Agilent Technologies Inc., Santa Clara, CA, USA), and the
image analysis was carried out using the ImaGene® 9 (miRCURY LNA™ microRNA Array Analysis
Software, Exiqon, Vedbaek, Denmark). The quantified signals were background corrected (Normexp
with offset value 10, see [107]), and normalized using the global Lowess (LOcally WEighted Scatterplot
Smoothing) regression algorithm.
4.5. Validation of miRNA Array Results by qRT-PCR
To confirm microarray results, quantitative real-time PCR (qRT-PCR) miRNA Taqman assays were
used (Thermo Fisher Scientific, Waltham, MA, USA). The reverse transcription reaction was performed
with the TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems, Thermo Fisher Scientific,
Waltham, MA, USA). Three-hundred and fifty nanograms from each sample was reverse transcribed
in the presence of 5× RT TaqMan® MicroRNA Assays (Applied Biosystems, Thermo Fisher Scientific,
Waltham, MA, USA) as described previously [108]. Briefly, 8 µL reaction mixture contained 0.2 µL
dNTPs, 1.5 µLMultiScribe ™ Reverse Transcriptase (50 U/µL), 0.8 µL 10× RT buffer, 0.9 µL MgCl2,
0.1 µL RNase inhibitor (20 U/µL), 1.5 µL 5× RT primer, and the template in a total volume of 3 µL.
Reverse transcription was carried out with the following cycling parameters in a thermocycler (Bioneer
Coorporation, Daejeon, Korea): 16 ◦C for 2 min, 42 ◦C for 1 min, 50 ◦C for 1 s, 45 cycles, then hold
the samples on 85 ◦C for 5 min. After dilution with 64 µL of water, 9 µL of the diluted reaction
mix was used as template in qRT-PCR. Reactions were performed on a RotorGene 3000 instrument
(Corbett Research, Sydney, Australia) with the TaqMan protocol. Twenty microliters of reaction mixture
contained 10 µL TaqMan® Universal PCR Master Mix (Applied Biosystems, Thermo Fisher Scientific,
Waltham, MA, USA), 1 µL of the TaqMan® MicroRNA Assays, and 9 µL of the diluted cDNA. To further
validate our data, we provided the relative expression level of each miRNA. We compared the average
Ct values of the samples and subtracted the average Ct value of miR-1, one of the most abundant
miRNA expressed in most tissues including the heart. miRNAs having values >10 correspond to low
abundance miRNA, while <6 denotes for high abundant miRNA (for details, see Table S2).
4.6. Prediction of miRNA Targets
To identify target genes of the differentially expressed miRNAs identified by miRNA microarray,
in silico target prediction approach was used to analyze miRNA–target interactions by miRNAtarget™
software (www.mirnatarget.com, Pharmahungary, Szeged, Hungary). In brief, the Norway rat specific
version of publicly available predicted and experimentally validated databases, i.e., miRDB version 5.0
(released in August, 2014), microRNA.org (released in August, 2010) and miRTarBase 4.5 were queried
by the miRNAtarget™, and score thresholds were applied to remove poor predictions (miRDB score ≤
80.0 and mirSVR score ≥ −1.2) as described [23].
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4.7. Selecting miRNA–Target Hubs
According to previous studies, the regulation of target genes by several miRNAs may be
synergistic exerting a major effect on the bioavailability of target mRNAs [109]. To find such miRNA
target hubs, a classical miRNA–target network was constructed by the miRNAtarget™ software in
which the nodes represented miRNAs and target genes, while edges symbolized miRNA–target
interactions. This miRNA–target network was visualized using the EntOptLayout plugin for
Cytoscape [110].
4.8. Validation of Predicted miRNA Target Genes at mRNA Levels
Total RNA was isolated from control and sensory desensitized hearts with TRI reagent according
to the manufacturer’s instructions (Molecular Research Center, Inc. Applied Biosystems, Thermo
Fischer Scientific, Waltham, MA, USA), followed by reverse transcription (MMLV, Moloney Murine
Leukemia Virus Reverse Transcriptase, 28025013, Thermo Fisher Scientific, Waltham, MA, USA).
To detect the transcript levels of insulin-like growth factor-1 (IGF-1), solute carrier family 2 facilitated
glucose transporter member 12 (SLC2a-12), eukaryotic translation initiation factor 4e (EIF-4e),
and Unc-51 like autophagy activating kinase 2 (ULK-2), quantitative PCR was carried out with
SYBR GREEN master mix (Fermentas, Thermo Fischer Scientific, Waltham, MA, USA) on a Light
Cycler 1.5 (Roche, Applied Science, Penzberg, Upper Bavaria, Germany). As an internal control,
GAPDH (Glycerinaldehyde-3-phosphate dehydrogenase) was amplified using the same heart samples.
Primer pairs for IGF-1, SLC2a-12, EIF-4e, ULK-2, and GAPDH were designed against sequences of
intron-spanning exons by Primer 3 Input software (Version 0.4.0; http://bioinfo.ut.ee/primer3-0.4.0/
primer3/input.htm) and tested to avoid primer dimers, non-specific amplification, and self-priming
by Primer-BLAST software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) (Table 6). Cycle
conditions were set as an initial denaturation step for 10 min at 95 ◦C, followed by 45 cycles of 10 s
at 95 ◦C for template denaturation, 10 s at 58 ◦C for annealing phase, and 10 s at 72 ◦C for extension.
Specificity of the PCR products was confirmed by melting curve analysis followed by verification of
the amplicon length on 1.5% agarose gels stained by ethidium bromide (Figure S2). To evaluate the
results, crossing point values (Cp) were calculated. 2−∆∆Cp methods were used to calculate relative
mRNA levels of IGF-1, ULK-2, SLC2a-12, and EIF-4e normalized to GAPDH mRNA level.
Table 6. Primer properties used in qRT-PCR for determination of transcript levels.
Target AccessionNumber Forward Primer Reverse Primer Efficiency
Product
Size (bp)
IGF-1 M15481.1 CAGTTCGTGTGTGGACCAAG GAGTCTTGGGCATGTCAGTG 1.966 211
SLC2a-12 NM_001107451.1 CCGAGACAAAGGGATGCTCT CCTTGTAAGTCCTGCCACCA 1.704 251
EIF-4e NM_053974.2 CAAGCAAACCTTCGGTTGAT CTCCCCGTTTGTTTTTCTCA 1.743 163
ULK-2 NM_001191645.1 CACAGAACGACCAATGGATG TTGTTCGAAGGACCATGTGA 2.00 161
GAPDH NM_017008.4 GCATCTTCTTGTGCAGTGCC GAGAAGGCAGCCCTGGTAAC 1.991 105
IGF-1, insulin-like growth factor 1; SLC2a-12, solute carrier family 2 facilitated glucose transporter member 12;
EIF-4e, eukaryotic translation initiation factor 4e; ULK-2, Unc-51 like autophagy activating kinase 2; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; and bp, base pair.
4.9. Statistical Analysis
Six heart samples from each vehicle and capsaicin treated groups were analyzed by microRNA
microarray. Three–three samples were pooled together and a total of 4 hybridization experiments
were carried out to gain raw data for statistical analysis. Altogether 4 individual parallel gene activity
comparisons were done to determine the average changes, standard deviations and p-values. Using
two-tailed two-sample unequal variance Student’s t-test, the p-value was determined and used to find
the significant gene expression changes. Gene expression ratio with p-value < 0.05 and log2 ratio <
−0.6 or log2 ratio > 0.6 (~1.5 fold change) are considered as repression and overexpression, respectively.
Changes in gene expression were plotted as log2 ratios of signal intensity values. Unpaired Student’s
t-test was performed to compare morphometric and echocardiographic data as well as the data for
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qRT-PCR at mRNA level by using GraphPad Prism software (Version 6.04, Inc.; San Diego, CA, USA).
All data showed normal distribution and are expressed as the mean ± SD. The level of p < 0.05 was
considered significant.
5. Conclusions
This is the first demonstration that sensory neuropathy induced by capsaicin desensitization
affects cardiac miRNA expression network targeting IGF-1, SLC2a-12, EIF-4e, and ULK-2, which
may contribute to cardiac diastolic dysfunction induced by sensory neuropathy. These results further
support the need for unbiased omics approach followed by in silico prediction and validation molecular
targets to reveal novel pathomechanisms, as recently recommended by a position paper from the
European Society for Cardiology [22].
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AMI acute myocardial infarction
EIF-4e eukaryotic translation initiation factor 4e
eNOS endothelial nitrogen monoxide synthase
GAPDH glycerinaldehyde-3-phosphate dehydrogenase
GLUT-4 glucose transporter type 4
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IGF-1 insulin-like growth factor-1
miRNA MicroRNA
MMLV Moloney Murine Leukemia Virus Reverse Transcriptase
mRNA messenger RNAs
MTI microRNA-target interaction
mTOR mammalian target of rapamycin
NO nitrogen monoxide
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ULK-2 Unc-51 like autophagy activating kinase 2
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